ConductScience.org, home

Comparison · NCT02373865-deaths

Arm A: Sitagliptin 100 mg+ Glimepiride-placebo (Adapted Dose) vs Arm B: Glimepiride (Adapted Dose) + Sitagliptin 100 mg Placebo: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm A: Sitagliptin 100 mg+ Glimepiride-placebo (Adapted Dose) vs Arm B: Glimepiride (Adapted Dose) + Sitagliptin 100 mg Placebo: deaths from any cause. Trial comparisons, record NCT02373865-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02373865-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.658wilson
Risk in group 2000.658wilson
Risk difference, group 1 minus group 20-0.6580.658newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm A: Sitagliptin 100 mg+ Glimepiride-placebo (Adapted Dose)
Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)~Sitagliptin: Sitagliptin will be given in a daily dosage of 100 mg~Glimepiride-Placebo: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
02EG000
Group 2Arm B: Glimepiride (Adapted Dose) + Sitagliptin 100 mg Placebo
Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo~Glimepiride: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg~Sitagliptin-Placebo: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
02EG001

Harm

What it counts
Total, all-cause mortality
Time frame

Source ClinicalTrials.gov

Trial

Title
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
NCT number
NCT02373865
Phases
PHASE4
Conditions
Diabetes Mellitus Type 2
Interventions
Sitagliptin, Glimepiride, Sitagliptin-Placebo, Glimepiride-Placebo
Lead sponsor
GWT-TUD GmbH
Results first posted
2019-02-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02373865-deaths